Greenfire Bio
Greenfire Bio operates as a life science development and investment company, led by a team of experienced biopharma executives, building a diversified product pipeline by developing early-stage assets through proof of concept and investing in unique medical breakthroughs. Greenfire typically licenses, acquires, partners, or invests in differentiated pre-clinical or early clinical-stage programs to bridge the translational medicine gap and accelerate development.
Pacylex Pharmaceuticals is focused on developing precision medicine solutions for various common cancers, including both blood and solid tumors. The company is advancing PCLX-001, a small molecule oral chemotherapeutic designed to induce selective lethality in cancer cells by targeting membrane-associated proteins involved in cancer signaling. This innovative approach aims to provide a potent alternative to traditional chemotherapies and immunotherapies. Additionally, Pacylex has created diagnostic technology to identify patients who are most likely to benefit from PCLX-001, thereby avoiding unnecessary treatments for those who would not respond. Founded in 2012 and based in Edmonton, Alberta, Canada, Pacylex Pharmaceuticals is pioneering first-in-kind therapies that may transform cancer treatment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.